According to a recent LinkedIn post from Beacon Therapeutics, Professor Szilárd Kiss is scheduled to present data from the company’s Phase 2 DAWN trial of investigational gene therapy laru-zova for X-linked retinitis pigmentosa at the 49th Macula Society Annual Meeting in San Diego. The presentation, focused on 9+ month safety, efficacy and surgical technique, is set for Friday, February 27.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights Beacon Therapeutics’ emphasis on gene therapy approaches for severe ocular diseases, positioning laru-zova as a potential treatment option in the rare disease segment. For investors, visibility at a specialist forum such as the Macula Society could help validate the program’s clinical progress, attract academic and industry interest, and potentially support future partnering or financing discussions.
While detailed trial results are not provided in the post, the focus on both safety and efficacy data suggests the company is advancing beyond early proof-of-concept. If DAWN data are viewed positively by the ophthalmology community, Beacon Therapeutics could strengthen its standing within the retinal gene therapy space, which may influence its valuation prospects and competitive positioning in XLRP.